VANC Pharmaceuticals Inc. (TSXV:VANC), a biopharma stock, climbed after announcing an agreement with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH)
A supply and distribution agreement with a cannabis company pushed a biopharma stock higher Tuesday. Here’s some small stocks making big moves on Tuesday, April 17, 2018 (as of 4 pm EST):
VANC Pharmaceuticals Inc. (TSXV:VANC), a biopharma stock, surged 29% to $0.31 on Tuesday after announcing that it has entered into a supply and distribution agreement with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies. At the same time, VANC issued to Emerald’s affiliate warrants to acquire 3,030,303 common shares of VANC Pharmaceuticals at $0.33 per share for a period of 24 months.
As well, shares of First Global Data Limited (TSXV:FGD) sank 30% to $0.095 as the international financial services technology company said it anticipates a delay in filing its audited financial statements, as it has discovered that a material number of software license agreements entered into between the Company and various arm’s length third parties may have revenue recognition issues.
RedZone Resources Inc. (TSXV:REZ), meanwhile, reported that its exploration drilling permit for the Lucky Mica Dyke at its Fornter Boyd lithium property in Arizona has been submitted. RedZone Resources stock moved up 6% to $0.27 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
VANC Pharmaceuticals Inc. (TSXV:VANC), a biopharma stock, surged 29% to $0.31 on Tuesday after announcing that it has entered into a supply and distribution agreement with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies. At the same time, VANC issued to Emerald’s affiliate warrants to acquire 3,030,303 common shares of VANC Pharmaceuticals at $0.33 per share for a period of 24 months.
